CML: Asciminib Bests Standard TKIs as Frontline Therapy

Asciminib demonstrated efficacy vs standard-of-care frontline TKIs in newly diagnosed patients with CML.

Related Keywords

New York ,United States ,Roswell Park ,Georgia ,Chicago ,Illinois ,American ,Jorgee Cortes ,Pankit Vachhani ,Eunice Wang ,University Of Alabama At Birmingham ,Drug Administration ,Georgia Cancer Center At Augusta University ,American Society Of Clinical Oncology ,Roswell Park Cancer Institute In Buffalo ,Georgia Cancer Center ,Augusta University ,American Society ,Clinical Oncology ,New England Journal ,Financial Toxicity ,Roswell Park Cancer Institute ,